A major concern during and/or after an interventional neuroradiology procedure is an ischemic event. The risk of intracranial hemorrhage associated with antiplatelet therapy is also a concern. Therefore it is critical to understand your patient’s level of response to their antiplatelet medications.
Not All Patients Respond Equally
Up to 1/3 of patients on antiplatelet medications may not be responding adequately to their antiplatelet medications.1
Numerous factors may contribute to inadequate response, including2 :
- Drug interactions (e.g. Proton Pump Inhibitors)
- Genetic polymorphisms (e.g. CYP2C19)
- Pre-existing health conditions (e.g. Diabetes)
- Non-compliance
Assessing response to antiplatelet therapy should be easy.
it is.
Backed by numerous peer-reviewed studies that demonstrate clinical utility and analytical performance, the VerifyNow System provides you with an easy, rapid and proven solution to help you assess your patient’s response to the following antiplatelet medications:
Click here to learn why you should join the growing number of neuroradiologists who utilize the VerifyNow System to improve their patient care.
- Dupont, AG. et al. Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome. Thromb Res. 2009 May;124(1):6-13.
- Maree, AO. et al. Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease. Circulation 2007;115:2196-2207.
- Hochholzer, W. et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation. 2005;111:2560-2564.
- Serebruany, VL. et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45(2):246-51.
